Epistem signs supply, distribution agreement with Becton Dickinson
The agreement includes an upfront payment of $1m with future milestone payments of up to $3m, alongside escalating supply volumes over the next five years. Genedrive provides a
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.